Delix Therapeutics

We are excited to announce the initiation of our Phase 1b clinical trial evaluating DLX-001, a novel #neuroplastogen, in patients with Major Depressive Disorder (MDD). MDD is a complex and widespread mental health condition that affects over 280 million people globally, including 21 million in the United States. Despite available treatment options, many patients do not experience a fast and durable response, highlighting the critical need for new and differentiated treatments.  This trial marks an important advancement in Delix's mission to pioneer cutting-edge #neurotherapeutics that enhance neuroplasticity and deliver transformative outcomes for patients. Discover more about our Phase 1b study: https://lnkd.in/d3EnxP6R.

Happy Thanksgiving from #TeamDelix!  We're grateful for the amazing team we get to work alongside every day — for the accomplishments we've achieved and the challenges we've overcome, for the people we've helped and the people we hope to one day help with our #neuroplastogens, and for the chance to lead a new era of #brainhealth.

Meet Delix Therapeutics’s Sr. Director, Medicinal Chemistry, Milan Chytil! From advancing our mission to develop novel #neuroplastogens for psychiatric disorders to transforming research into groundbreaking solutions, Milan plays a vital role in shaping the future of #CNS treatments. Leading a high-performing team of medicinal chemists, Milan drives innovation in complex drug discovery, developing life-changing therapies for those who need them most. We’re grateful for his expertise as we continue to push the boundaries of #neuroscience.

Mark your calendar for the 63rd Annual Meeting of the American College of Neuropsychopharmacology, taking place December 8–11 in Phoenix, Arizona! Join us as our Senior Director of Pharmacology, Stephanie M., Ph.D. presents the groundbreaking potential of our lead #neuroplastogen, DLX-001, for treating a range of #neuropsychiatric disorders. Our Chief Scientific Officer, Kurt Rasmussen, Ph.D., will discuss advancements in our other non-hallucinogenic therapies, including DLX-159, while our Chief Medical Officer, Aaron Koenig MD, will showcase compelling Phase 1 results for DLX-001, highlighting its potential in treating Major Depressive Disorder. Don’t miss this opportunity to connect with our team and learn about the future of #brainhealth innovation. Register today: https://lnkd.in/dyWhDU5F

#Psychedelics hold immense promise for treating #neuropsychiatric disorders, but can scientists separate their therapeutic benefits from hallucinatory effects? In a groundbreaking study published in Science Magazine, Delix Therapeutics’s Co-Founder and Chief Innovation Officer, Professor David E. Olson, and the researchers at the University of California, Davis and UC Davis Institute for Psychedelics and Neurotherapeutics, leverage innovative neuronal reactivation techniques to uncover distinct neural circuits responsible for the therapeutic, anxiolytic effects versus the hallucinatory effects. This research strongly supports Delix’s underlying thesis and validates the feasibility of developing non-hallucinogenic #neuroplastogens that deliver the therapeutic benefits of psychedelics—safely, effectively, and at scale. Learn more about this exciting breakthrough: https://lnkd.in/eU9cB7U9

Members and families of #TeamDelix spent a Sunday afternoon enjoying a beautiful fall day together, picking apples, soaking in the fresh air, and sharing lots of laughs. We also took a break from the office to enjoy a spirited game of darts, complete with friendly competition and some impressive bullseyes. At Delix Therapeutics, we value hard work, collaboration, and connection both in and outside the office. These moments outside of work bring our team even closer together, strengthening our commitment to the important work we do to advance #brainhealth.

Meet Retsina Meyer, PhD, Head of Corporate Strategy at Delix Therapeutics!  Whether it is working to help drive our strategic imperatives, navigating business development efforts, or engaging with potential partners, Retsina works closely with #TeamDelix to tackle complex challenges and foster growth in #brainhealth. Her leadership supports the teams across Delix in advancing #CNS treatments and developing novel #neuroplasticity therapies that are shaping the future of patient care.  We’re grateful for Retsina’s expertise and commitment to the Delix team and patients in support of transforming lives through cutting-edge solutions and groundbreaking treatments for those who need them most. 

Join Delix Therapeutics CEO, Mark Rus, at the Longwood Healthcare Leaders CEO event in Boston, MA on October 28–29, where he and fellow CEO panelists will speak on ‘Identifying Next Generation Therapeutics’. Hear about Delix's innovative pipeline of rapid-acting #neuroplastogens for a broad range of significant unmet needs in neuropsychiatry, neurology, and beyond.  For this panel and more, register here: https://lnkd.in/dJ_8trZM.   Cc Rosana Kapeller from ROME Therapeutics, Oliver Rosen from Akamis Bio, Paul Peter Tak, MD PhD FMedSci from Candel Therapeutics, and Brian Taylor from SmartLabs #longwoodhealthcareleaders #NextGenTherapeutics

🌍 A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. 🧠 With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters

Tomorrow, we stand with the global community in observing World Alzheimer's Day, a day dedicated to raising awareness and challenging the stigma surrounding #Alzheimer’s disease. With nearly 55 million people affected worldwide, it's more important than ever to support ongoing research and foster a deeper understanding of this disease as we strive for better treatments for patients and their families. At Delix, we’re harnessing the brain’s innate ability to repair and restore neurons to treat a broad range of neurological illnesses. Our innovative #neuroplastogens have the potential to revolutionize the treatment of a range of #CNS conditions, including Alzheimer's. Discover more about our innovative approach here: https://lnkd.in/dqnHGFyw